JAK-STAT Signaling in Inflammatory Breast Cancer Enables Chemotherapy-Resistant Cell States

Overview

Journal Cancer Res

Specialty Oncology

Date 2022 Nov 21

PMID 36409824

Authors

Laura E Stevens

Guillermo Peluffo

Xintao Qiu

Daniel Temko

Anne Fassl

Zheqi Li

Anne Trinh

Marco Seehawer

Bojana Jovanovic

Masa Aleckovic

Callahan M Wilde

Renee C Geck

Shaokun Shu

Natalie L Kingston

Nicholas W Harper

Vanessa Almendro

Alanna L Pyke

Shawn B Egri

Malvina Papanastasiou

Kendell Clement

Ningxuan Zhou

Sarah Walker

Jacqueline Salas

So Yeon Park

David A Frank

Alexander Meissner

Jacob D Jaffe

Piotr Sicinski

Alex Toker

Franziska Michor

Henry W Long

Beth A Overmoyer

Kornelia Polyak

Affiliations

Soon will be listed here.

Abstract

Significance: Chemotherapy resistance in inflammatory breast cancer is driven by the JAK2/STAT3 pathway, in part via cAMP/PKA signaling and a cell state switch, which can be overcome using paclitaxel combined with JAK2 inhibitors.

Citing Articles

Targeting the Leukemia Inhibitory Factor/Leukemia Inhibitory Factor Receptor Axis Reduces the Growth of Inflammatory Breast Cancer by Promoting Ferroptosis.

Romo B, Fuentes Z, Randolph L, Mahajan M, Aller E, Ebrahimi B Cancers (Basel). 2025; 17(5).

PMID: 40075639 PMC: 11898489. DOI: 10.3390/cancers17050790.

Liver Metastasis in Cancer: Molecular Mechanisms and Management.

Xu W, Xu J, Liu J, Wang N, Zhou L, Guo J MedComm (2020). 2025; 6(3):e70119.

PMID: 40027151 PMC: 11868442. DOI: 10.1002/mco2.70119.

Advance in identified targets of berberine.

Sun P, Wang Z, Ma Y, Liu Y, Xue Y, Li Y Front Pharmacol. 2025; 16:1500511.

PMID: 39944624 PMC: 11814165. DOI: 10.3389/fphar.2025.1500511.

Omega-3 fatty acids: molecular weapons against chemoresistance in breast cancer.

Marchio V, Augimeri G, Morelli C, Vivacqua A, Giordano C, Catalano S Cell Mol Biol Lett. 2025; 30(1):11.

PMID: 39863855 PMC: 11762563. DOI: 10.1186/s11658-025-00694-x.

STEAP3 is a potential preliminary prognostic biomarker of glioblastoma.

Zhang W, Xie M, Huang Q, Liu H, Liu J, Sun X Sci Rep. 2024; 14(1):30994.

PMID: 39730631 PMC: 11681130. DOI: 10.1038/s41598-024-82145-9.

References

Li H, Durbin R . Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics. 2009; 25(14):1754-60. PMC: 2705234. DOI: 10.1093/bioinformatics/btp324. View

McKenna A, Hanna M, Banks E, Sivachenko A, Cibulskis K, Kernytsky A . The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res. 2010; 20(9):1297-303. PMC: 2928508. DOI: 10.1101/gr.107524.110. View

Vermeulen P, van Golen K, Dirix L . Angiogenesis, lymphangiogenesis, growth pattern, and tumor emboli in inflammatory breast cancer: a review of the current knowledge. Cancer. 2010; 116(11 Suppl):2748-54. DOI: 10.1002/cncr.25169. View

Khan M, Saadalla A, Ewida A, Al-Katranji K, Al-Saoudi G, Giaccone Z . The STAT3 inhibitor pyrimethamine displays anti-cancer and immune stimulatory effects in murine models of breast cancer. Cancer Immunol Immunother. 2017; 67(1):13-23. PMC: 5783191. DOI: 10.1007/s00262-017-2057-0. View

Matsuda N, Lim B, Wang Y, Krishnamurthy S, Woodward W, Alvarez R . Identification of frequent somatic mutations in inflammatory breast cancer. Breast Cancer Res Treat. 2017; 163(2):263-272. DOI: 10.1007/s10549-017-4165-0. View

Robinson M, McCarthy D, Smyth G . edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics. 2009; 26(1):139-40. PMC: 2796818. DOI: 10.1093/bioinformatics/btp616. View

Wang S, Sun H, Ma J, Zang C, Wang C, Wang J . Target analysis by integration of transcriptome and ChIP-seq data with BETA. Nat Protoc. 2013; 8(12):2502-15. PMC: 4135175. DOI: 10.1038/nprot.2013.150. View

Iwamoto T, Bianchini G, Qi Y, Cristofanilli M, Lucci A, Woodward W . Different gene expressions are associated with the different molecular subtypes of inflammatory breast cancer. Breast Cancer Res Treat. 2010; 125(3):785-95. PMC: 4109066. DOI: 10.1007/s10549-010-1280-6. View

Balko J, Giltnane J, Wang K, Schwarz L, Young C, Cook R . Molecular profiling of the residual disease of triple-negative breast cancers after neoadjuvant chemotherapy identifies actionable therapeutic targets. Cancer Discov. 2013; 4(2):232-45. PMC: 3946308. DOI: 10.1158/2159-8290.CD-13-0286. View

10.

Marotta L, Almendro V, Marusyk A, Shipitsin M, Schemme J, Walker S . The JAK2/STAT3 signaling pathway is required for growth of CD44⁺CD24⁻ stem cell-like breast cancer cells in human tumors. J Clin Invest. 2011; 121(7):2723-35. PMC: 3223826. DOI: 10.1172/JCI44745. View

11.

Anders S, Pyl P, Huber W . HTSeq--a Python framework to work with high-throughput sequencing data. Bioinformatics. 2014; 31(2):166-9. PMC: 4287950. DOI: 10.1093/bioinformatics/btu638. View

12.

Garrido-Castro A, Lin N, Polyak K . Insights into Molecular Classifications of Triple-Negative Breast Cancer: Improving Patient Selection for Treatment. Cancer Discov. 2019; 9(2):176-198. PMC: 6387871. DOI: 10.1158/2159-8290.CD-18-1177. View

13.

Bieche I, Lerebours F, Tozlu S, Espie M, Marty M, Lidereau R . Molecular profiling of inflammatory breast cancer: identification of a poor-prognosis gene expression signature. Clin Cancer Res. 2004; 10(20):6789-95. DOI: 10.1158/1078-0432.CCR-04-0306. View

14.

Woodward W, Krishnamurthy S, Yamauchi H, El-Zein R, Ogura D, Kitadai E . Genomic and expression analysis of microdissected inflammatory breast cancer. Breast Cancer Res Treat. 2013; 138(3):761-72. PMC: 3677826. DOI: 10.1007/s10549-013-2501-6. View

15.

Hollern D, Swiatnicki M, Andrechek E . Histological subtypes of mouse mammary tumors reveal conserved relationships to human cancers. PLoS Genet. 2018; 14(1):e1007135. PMC: 5773092. DOI: 10.1371/journal.pgen.1007135. View

16.

Opyrchal M, Salisbury J, Iankov I, Goetz M, McCubrey J, Gambino M . Inhibition of Cdk2 kinase activity selectively targets the CD44⁺/CD24⁻/Low stem-like subpopulation and restores chemosensitivity of SUM149PT triple-negative breast cancer cells. Int J Oncol. 2014; 45(3):1193-9. PMC: 4121417. DOI: 10.3892/ijo.2014.2523. View

17.

Bodenmiller B, Zunder E, Finck R, Chen T, Savig E, Bruggner R . Multiplexed mass cytometry profiling of cellular states perturbed by small-molecule regulators. Nat Biotechnol. 2012; 30(9):858-67. PMC: 3627543. DOI: 10.1038/nbt.2317. View

18.

Shu S, Wu H, Ge J, Zeid R, Harris I, Jovanovic B . Synthetic Lethal and Resistance Interactions with BET Bromodomain Inhibitors in Triple-Negative Breast Cancer. Mol Cell. 2020; 78(6):1096-1113.e8. PMC: 7306005. DOI: 10.1016/j.molcel.2020.04.027. View

19.

Nikolsky Y, Nikolskaya T, Bugrim A . Biological networks and analysis of experimental data in drug discovery. Drug Discov Today. 2005; 10(9):653-62. DOI: 10.1016/S1359-6446(05)03420-3. View

20.

Cibulskis K, Lawrence M, Carter S, Sivachenko A, Jaffe D, Sougnez C . Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat Biotechnol. 2013; 31(3):213-9. PMC: 3833702. DOI: 10.1038/nbt.2514. View